San Antonio Breast Cancer Symposium (SABCS) | Conference

Neratinib Combo Yields Positive ORR in HER2-Mutant Metastatic Breast Cancer
December 18, 2021

Patients with HER2-mutant breast cancer given neratinib combinations saw improved efficacy.

CancerNetwork® Recaps Tarantino’s Twitter Takeover at SABCS 2021
December 17, 2021

Paolo Tarantino, MD, hosted a Twitter Takeover during the San Antonio Breast Cancer Symposium where he discussed abstract presentations and key takeaways in a #CNRealTimeReport.

Patient Race Doesn’t Significantly Impact Pathological CR After Neoadjuvant Therapy for Breast Cancer
December 10, 2021

Research from the 2021 San Antonio Breast Cancer Symposium suggests pathologic complete response and event-free survival were not significantly impacted by race for women with high-risk breast cancer who underwent targeted neoadjuvant chemotherapy.

Adverse Effects From Olaparib Can Be Amenable in High-Risk Early Breast Cancer Subset
December 10, 2021

Patients with gremlin BRCA1/2 mutations and high-risk HER2-negative early breast cancer can have amenable adverse effects after being treated with chemotherapy before utilize olaparib.

Artificial Intelligence–Based Whole Slide Scoring Accurately Identified Status for Several Key Breast Cancer Markers
December 10, 2021

Investigators were able to identify breast cancer immunohistochemistry markers including Ki-67, estrogen receptor, and progesterone receptor status utilizing deep learning–based artificial intelligence algorithms

Samuraciclib Plus Fulvestrant Shows Tumor Shrinkage in HR+ Breast Cancer
December 10, 2021

Patients with hormone receptor-positive breast cancer who were treated with samuraciclib plus fulvestrant saw tumor activity.

Utilization of ctDNA Helps to Identify Relapse in Triple-Negative Breast Cancer
December 10, 2021

Circulating tumor DNA should be utilized early to help detect relapse in patients with triple-negative breast cancer.

T-DXd Prolongs Survival as Second-Line Therapy for HER2+ Metastatic Breast Cancer
December 10, 2021

Second-line fam-trastuzumab deruxtecan-nxki prolonged survival and led to higher responses over ado-trastuzumab emtansine for patients with HER2-positive metastatic breast cancer.

Pyrotinib Produces Improved Survival vs Lapatinib in HER2-Positive Breast Cancer
December 09, 2021

Patients with HER2-positive breast cancer appeared to derive a higher overall survival benefit after being treated with pyrotinib plus capecitabine vs lapatinib plus capecitabine.

Reduction in Risk of Distinct Recurrence by Adjuvant Therapies in HER2-Positive Early Stage Breast Cancer
December 09, 2021

Utilizing neratinib or abo-trastuzumab emtansine for patients with HER2-positive early stage breast cancer reduced the risk of distant recurrence.